Drug development is dynamic and engages CMC regulatory input at each step. It’s common to focus on the high-level, current tasks, without thinking more holistically about the CMC regulatory process and your molecule’s lifecycle. With a high-level focus, important steps and regulatory requirements are often missed, which can cause lengthy delays or additional costs to your project. As a result, it’s important to proactively plan and develop CMC regulatory strategies early on in your development process.
Attend this webinar to learn more about:
Betty Thompson provides expertise in small molecule drugs, oral solid, oral solutions, and sterile injectable dosage forms across all product life cycle stages as part of Thermo Fisher Scientific’s North American Regulatory Affairs team. Betty is a CMC regulatory affairs professional with seventeen years of experience in a consulting environment. She received a Bachelor of Science in Applied Chemistry- Cooperative Program from University of Waterloo, Ontario, Canada. In addition to this, she also has a Regulatory Affairs Certification (RAC) from the Regulatory Affairs Professionals Society.
NOW AVAILABLE ON-DEMAND